Dania
Daye1, 2, Suzanne Wehrli3, George Belka4,
Anthony Mancuso5, Chris Sterner6, Mitchell Schnall5,
Lewis Chodosh
1Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA, United States; 2Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, PA, United States; 3Children's Hospital of Philadelphia; 4Department of Cancer Biology , Perelman School of Medicine at the University of Pennsylvania; 5Department of Radiology, Perelman School of Medicine at the University of Pennsylvania; 6Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania
Tumor recurrence represents the principal cause of death from breast cancer. Despite being a critical clinical problem, little is known about the cellular and molecular mechanisms underlying tumor recurrence. Our laboratory has developed an inducible transgenic mouse model that accurately reproduces key features of the natural history of human breast cancer progression including tumor recurrence. Dysregulated metabolism has been shown to be key feature of tumorigenesis. To date, very little is know about the association between changes in metabolism and cancer recurrence. In this study, we investigate the role of 13C-glutamine as a potential breast cancer progression marker using MRS.